Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites

Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites

Background: House dust mite (HDM) allergies are prevalent, yet current treatments like allergen avoidance, pharmacotherapy, and conventional allergen immunotherapy present limitations. The novel LAMP (lysosomal-associated membrane protein)-based DNA vaccine ASP2390 targets major HDM allergens, poten...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas Kayser, MD, BS, Ronald Smulders, MD, PhD, Tomohiro Kusawake, PhD, Erik Wambre, PhD, Gurunadh R. Chichili, PhD, Mary B. Blauwet, DrPH, Anna Spence, MS, Melanie Patton, BS, Rima Tabash, PhD, Hannah A. DeBerg, PhD, Sugandhika Khosa, MS, Philipp Badorrek, MD, Jens M. Hohlfeld, MD, Brian C. Ferslew, PharmD, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Allergen immunotherapy
allergy
ASP2390
clinical trial
house dust mite
immunologic response
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829325000050
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items